Skip to main content

Table 2 Summary results from mixed model analysis of primary and secondary outcomes (change from baseline in score) at 24 weeks and 48 weeks by treatment group

From: A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

Primary and secondary outcomes

Outcomes

Visit (weeks)

Mixed model analysis

Dolutegravir

Efavirenz

Difference from baseline (95% CI)

p-valuea

Difference from baseline (95% CI)

p-valueb

Primary outcomes

Physical health summary

24

10.40 (9.24, 11.55)

< 0.0001

10.24 (9.10, 11.38)

< 0.0001

48

14.32 (13.08, 15.57)

< 0.0001

13.90 (12.70, 15.11)

< 0.0001

Mental health summary

24

9.23 (7.35, 11.10)

< 0.0001

7.54 (5.66, 9.42)

< 0.0001

48

12.50 (10.49, 14.51)

< 0.0001

12.63 (10.63, 14.63)

< 0.0001

Secondary outcomes

Role function

24

6.87 (6.14, 7.60)

< 0.0001

5.76 (5.04, 6.49)

< 0.0001

48

6.87 (6.48, 7.26)

< 0.0001

6.87 (6.49, 7.26)

< 0.0001

Physical function

24

16.92 (15.67, 18.17)

< 0.0001

13.95 (12.72, 15.19)

< 0.0001

48

18.22 (17.51, 18.93)

< 0.0001

18.18 (17.49, 18.88)

< 0.0001

Social function

24

10.94 (10.15, 11.73)

< 0.0001

11.19 (10.41, 11.97)

< 0.0001

48

12.53 (12.04, 13.02)

< 0.0001

12.28 (11.80, 12.76)

< 0.0001

Pain

24

10.91 (8.87, 12.94)

< 0.0001

12.57 (10.54, 14.59)

< 0.0001

48

15.42 (13.69, 17.14)

< 0.0001

13.71 (12.01, 15.41)

< 0.0001

General health

24

1.63 (0.55, 2.72)

0.0032

1.88 (0.80, 2.96)

0.0007

48

4.26 (3.36, 5.17)

< 0.0001

4.27 (3.38, 5.17)

< 0.0001

Health transition

24

12.07 (8.30, 15.84)

< 0.0001

12.58 (8.81, 16.35)

< 0.0001

48

11.95 (8.60, 15.30)

< 0.0001

9.79 (6.45, 13.12)

< 0.0001

Quality of life

24

12.36 (9.28, 15.45)

< 0.0001

9.76 (6.65, 12.86)

< 0.0001

48

14.89 (12.15, 17.63)

< 0.0001

13.59 (10.85, 16.33)

< 0.0001

Health distress

24

15.10 (12.45, 17.75)

< 0.0001

11.99 (9.35, 14.63)

< 0.0001

48

19.33 (17.10, 21.55)

< 0.0001

19.93 (17.74, 22.13)

< 0.0001

Cognitive function

24

2.30 (0.31, 4.29)

0.0236

4.97 (2.99, 6.95)

< 0.0001

48

6.60 (4.88, 8.33)

< 0.0001

6.50 (4.79, 8.21)

< 0.0001

Energy

24

15.49 (13.14, 17.85)

< 0.0001

15.86 (13.51, 18.20)

< 0.0001

48

22.90 (20.90, 24.89)

< 0.0001

21.43 (19.46, 23.40)

< 0.0001

Mental health

24

8.57 (6.44, 10.70)

< 0.0001

6.43 (4.32, 8.54)

< 0.0001

48

11.49 (9.70, 13.29)

< 0.0001

12.26 (10.50, 14.03)

< 0.0001

  1. aP-values for estimated differences in dolutegravir
  2. bP-vaules for estimated differences in efavirenz